Lloyd Bibby is a consultant whose CI expertise spans a diverse range of therapy areas and indications, including infectious diseases and oncology. Lloyd is a seasoned CI professional with expertise in primary and secondary research, as well as in-person conference coverage for medical congresses.
Prior to joining LSD, Lloyd worked in both academia and the pharmaceutical industry, collaborating with stakeholders across the health care and pharmaceutical sectors to develop cutting-edge technology for diagnosis and patient risk stratification across multiple therapy areas. Lloyd has a passion for business strategy and innovation in the health care and biotechnology sectors.
Long-acting HIV therapies promise greater convenience, but fewer doses alone may not solve adherence or access challenges. Lloyd Bibby and Pooja Goyal, MS(Pharm), discuss patient choice, weekly oral and injectable therapies, health system capacity, equitable access, and the real-world measures that will define success.